The U.S. Supreme Court on Thursday preserves access to mifepristone, a widely used medication used in a common method of medication abortion, while litigation over potential restrictions continues in lower courts. Multiple outlets report that the Court rejected lower-court restrictions for now, issuing an order that keeps current access in place as the case moves through the judicial process. STAT and MedPage Today describe the decision as a temporary extension of access, meaning the restrictions being challenged do not take effect while the Supreme Court considers the legal issues. Other coverage similarly characterizes the ruling as maintaining women’s access to mifepristone and allowing abortions to proceed using the drug under existing rules. The Hindu notes the broader context of ongoing abortion disputes following the Court’s decision four years earlier to overturn Roe v. Wade and enable states to impose far-reaching abortion limits. Together, the reports indicate the Supreme Court’s action is a stopgap measure that maintains availability of the drug during the pendency of the lawsuit.